Oppenheimer Issues Positive Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its target price boosted by analysts at Oppenheimer from $130.00 to $150.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Oppenheimer's price target points to a potential upside of 21.40% from the company's current price.

Several other research firms have also recently weighed in on TMDX. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Tuesday. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Finally, Piper Sandler reissued an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $127.33.

TransMedics Group Trading Down 0.4%

NASDAQ TMDX traded down $0.44 on Tuesday, reaching $123.56. 1,290,484 shares of the company were exchanged, compared to its average volume of 1,367,615. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. The business's fifty day moving average price is $113.37 and its 200 day moving average price is $83.69. The stock has a market capitalization of $4.18 billion, a P/E ratio of 90.85 and a beta of 2.10. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The firm had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. During the same quarter in the previous year, the company posted $0.35 EPS. The company's revenue was up 48.2% compared to the same quarter last year. Analysts forecast that TransMedics Group will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider now directly owns 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock valued at $1,512,613 over the last quarter. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Baillie Gifford & Co. lifted its holdings in TransMedics Group by 14.9% during the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after buying an additional 34,947 shares in the last quarter. State of Michigan Retirement System purchased a new stake in shares of TransMedics Group during the fourth quarter worth $6,734,000. Peregrine Capital Management LLC raised its stake in shares of TransMedics Group by 64.0% in the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock valued at $4,124,000 after acquiring an additional 25,814 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of TransMedics Group by 41.3% in the fourth quarter. Oppenheimer & Co. Inc. now owns 63,424 shares of the company's stock valued at $3,954,000 after acquiring an additional 18,531 shares in the last quarter. Finally, Emerald Advisers LLC boosted its holdings in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after purchasing an additional 220,804 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.